title: Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana.
abstract: BACKGROUND
  Few data are available on cutaneous leishmaniasis caused by dermotropic species in human immunodeficiency virus (HIV)-infected patients.
  
  
  OBJECTIVE
  To describe nine cases of cutaneous leishmaniasis in HIV+ patients and to compare their clinical features and their response to treatment with those of HIV- patients with the forms of leishmaniasis commonly found in French Guiana.
  
  
  METHODS
  A case-control study was carried out between July 1994 and December 2000 in French Guiana. We compared the following variables in nine HIV-infected patients with leishmaniasis and 27 matched controls: clinical type of leishmaniasis, number of lesions, presence of lymphangitis and adenopathy, the rate of recovery after treatment, and recurrence or reinfection.
  
  
  RESULTS
  Eight of the HIV-infected patients had localized cutaneous leishmaniasis and one had mucocutaneous leishmaniasis. All of the controls had localized cutaneous leishmaniasis. Leishmania guyanensis was the only species isolated from HIV-infected subjects. HIV-Leishmania coinfected patients had a higher rate of recurrence or reinfection (P < 0.02) and a lower rate of recovery after one treatment cycle with pentamidine (P < 0.02) than did HIV- subjects. The CD4+ lymphocyte counts exceeded 200 mm(-3) in all HIV+ patients at the time of the diagnosis with leishmaniasis.
  
  
  CONCLUSIONS
  In French Guiana, cutaneous leishmaniasis in moderately immunosuppressed HIV-infected subjects (> 200 CD4+ T cells mm(-3)) is characterized by a higher rate of recurrence or reinfection and is more difficult to treat than that in HIV- subjects.
authors.affiliation: Institut Guyanais de Dermatologie Tropicale, Service de Dermatologie, Centre Hospitalier de Cayenne, Rue des Flamboyants, BP 6006, 97300 Cayenne, French Guiana. couppie.pierre@voila.fr
authors.forename: P
authors.initials: P
authors.lastname: Couppié
authors.forename: E
authors.initials: E
authors.lastname: Clyti
authors.forename: M
authors.initials: M
authors.lastname: Sobesky
authors.forename: F
authors.initials: F
authors.lastname: Bissuel
authors.forename: P
authors.initials: P
authors.lastname: Del Giudice
authors.forename: D
authors.initials: D
authors.lastname: Sainte-Marie
authors.forename: J P
authors.initials: JP
authors.lastname: Dedet
authors.forename: B
authors.initials: B
authors.lastname: Carme
authors.forename: R
authors.initials: R
authors.lastname: Pradinaud
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D000328:Adult; D000368:Aged; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010419:Pentamidine; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D000981:Antiprotozoal Agents; D010419:Pentamidine